A parent is told that an infusion of stem cells will help their autistic child. The clinic is registered. The doctor holds a valid medical degree. The invoice is legitimate. Nothing about the transaction looks illegal.
Everything about it, the Supreme Court has now held, was outside the law.
On 17 September 2026 the Ministry of Health and Family Welfare published an advisory it had issued the previous day to States and Union Territories, setting out what stem cell therapy may and may not be offered as. The advisory flows from a judgment of the Supreme Court dated 30 January 2026 in Yash Charitable Trust & Ors. v. Union of India & Ors., W.P. (C) No. 369 of 2022, reported as 2026 INSC 96.
The instruction is compressed into three propositions:
- Stem cell therapy may be offered as standard care in routine clinical practice only for the disease conditions and indications on the list approved by the Ministry of Health and Family Welfare.
- For Autism Spectrum Disorder (ASD), therapeutic use of any type of stem cell is restricted to duly approved clinical trials.
- Unproven stem cell interventions, including stem cell therapy for ASD, are not to be offered as routine, standard or commercial clinical services.
The third proposition is the operative one. It does not ban research. It bans selling.
What a stem cell actually is
The therapeutic claim rests on one real property: a stem cell is undifferentiated and can both renew itself and become a specialised cell type. Everything else depends on which stem cell, and how much it can become.
Totipotent cells can form every cell type including the placenta — only the fertilised egg and its earliest divisions.
Pluripotent cells can form any cell of the body but not the supporting placental tissue. Embryonic stem cells are the classical example.
Multipotent cells are restricted to a family of related types. Haematopoietic stem cells in bone marrow make blood and immune cells and nothing else. Mesenchymal stem cells make bone, cartilage and fat lineages.
Induced pluripotent stem cells (iPSCs) are adult cells reprogrammed back to a pluripotent state, a technique for which Shinya Yamanaka shared the 2012 Nobel Prize in Physiology or Medicine with John Gurdon. iPSCs matter because they sidestep the ethical objection to destroying embryos and because they can be made from the patient's own cells, avoiding immune rejection.
Now the crucial distinction, and the one the whole controversy turns on.
One family of stem cell treatments is long established and unquestionably works: haematopoietic stem cell transplantation — bone marrow or cord blood transplant — used for leukaemias, lymphomas, aplastic anaemia, thalassaemia and certain immune deficiencies. It has decades of trial evidence and a clear mechanism: the diseased blood-forming system is replaced with a healthy one.
Around that established core has grown a large commercial fringe offering stem cell infusions for conditions where no such mechanism exists and no trial evidence supports the claim — autism, cerebral palsy, muscular dystrophy, spinal cord injury, ageing. The marketing borrows the credibility of the proven core and applies it to the unproven fringe. That borrowing is precisely what the approved-indications list is designed to stop.
The scientific difficulty in ASD is specific. Autism is a neurodevelopmental condition with no single identified lesion for an infused cell to repair, and its natural course includes genuine developmental gains over time. A child who receives an infusion and improves over the following year may well have improved anyway. Without a control arm, parental hope and normal development are indistinguishable from treatment effect. That is what a clinical trial exists to separate, and it is why "but the families report improvement" is not an answer.
The regulatory architecture
Four instruments do the work here, and questions test which one is operating.
National Guidelines for Stem Cell Research, 2017, issued jointly by the Indian Council of Medical Research (ICMR) and the Department of Biotechnology (DBT). This is the governing framework. Its central rule is that apart from haematopoietic stem cell use for accepted indications, every other use of stem cells is investigational and must go through approved research channels.
Clinical Establishments (Registration and Regulation) Act, 2010. The Supreme Court pointed to Sections 32 and 40, which provide for cancellation of registration and penalty. This is the lever against the institution — the clinic or hospital itself.
Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002, specifically Regulation 7.22, under which the conduct constitutes professional misconduct. This is the lever against the individual practitioner.
The National Medical Commission (NMC), which replaced the Medical Council of India under the NMC Act, 2019, reinforced the position in its own advisory dated 5 September 2026: stem cell therapy may be offered as standard clinical care only for approved indications, and unauthorised administration, prescription, promotion or advertisement beyond those indications amounts to professional misconduct. The NMC has asked State Medical Councils to examine alleged violations and take disciplinary action after due process.
Note how the enforcement is layered. The clinic can lose its registration. The doctor can be struck off. The advertisement is itself actionable. A regime that only punished the treatment would leave the marketing untouched, and the marketing is where the harm begins.
The constitutional detail hiding in one phrase
The advisory is addressed to "States and Union Territories that have adopted the Clinical Establishments (Registration and Regulation) Act, 2010."
That qualifier is not bureaucratic caution. It is a constitutional fact, and it is the most examinable thing in this entire story.
Public health and sanitation, hospitals and dispensaries is Entry 6 of the State List — Parliament cannot ordinarily legislate on it. The Clinical Establishments Act exists because of Article 252, which allows Parliament to legislate on a State List subject for two or more States whose legislatures pass resolutions requesting it, with the law then applying to any other State that adopts it by a similar resolution.
The requesting States were Arunachal Pradesh, Himachal Pradesh, Mizoram and Sikkim. The Act applies in the first instance to those four and to the Union Territories, taking effect from 1 March 2012. Several States — including Uttar Pradesh, Uttarakhand, Rajasthan, Bihar, Jharkhand and Assam — have adopted it subsequently. States that have not adopted it are outside its reach, and regulate clinical establishments under their own laws or not at all.
This explains the entire posture of the document. The Centre advises; it does not command. It asks States to disseminate the Court's directions to State and District Regulatory Authorities. Where the Act has not been adopted, the enforcement lever against the clinic simply does not exist — though the NMC route against the individual doctor still does, because medical registration is regulated centrally.
Article 252 sits alongside Article 249 (Rajya Sabha resolution by two-thirds majority, in the national interest, for up to a year) and Article 250 (during a Proclamation of Emergency) as the routes by which Parliament reaches the State List. The distinguishing feature of Article 252 is that it is voluntary and State-initiated, and that the resulting law can be amended or repealed only by Parliament, not by the adopting State. Our CDS/OTA polity notes set out the full set of exceptions to the ordinary distribution of legislative power.
What the judgment did and did not do
It is worth being precise, because overstatement is common in coverage of this case.
The judgment did not ban stem cell research in autism. It routed it into approved clinical trials conducted under the 2017 ICMR-DBT guidelines. If a trial produces evidence of benefit, the indication can enter the approved list by the ordinary route.
The judgment did not declare stem cell therapy ineffective. It drew a line between indications supported by evidence and indications supported by hope, and held that only the first may be sold as treatment.
The judgment did attach consequences. At Para 151(xiii) it held that non-compliance with the statutory mandate must attract consequences — professional misconduct under the 2002 Regulations, and action under Sections 32 and 40 of the 2010 Act.
The broader principle is the one worth carrying into an interview: compassion is not a regulatory category. The argument that desperate families should be free to try anything sounds humane and fails on inspection, because an unproven paid intervention transfers money and risk to the patient while returning no knowledge to anyone. A trial, by contrast, gives the same family the same chance of benefit and produces an answer that helps the next family. Channelling desperate demand into trials is not a restriction on hope. It is the only arrangement under which hope eventually becomes evidence.
🔑 Revision block
The chain of events. Supreme Court judgment, 30 January 2026 — Yash Charitable Trust & Ors. v. Union of India & Ors., W.P. (C) No. 369 of 2022, 2026 INSC 96 → NMC advisory, 5 September 2026 → MoHFW advisory, 16 September 2026 to States and UTs → PIB release, 17 September 2026.
The three rules. Stem cell therapy as standard care only for MoHFW-approved indications · Autism Spectrum Disorder: therapeutic use of any stem cell restricted to approved clinical trials · Unproven interventions not to be offered as routine, standard or commercial services.
Stem cell types. Totipotent — every cell type including placenta. Pluripotent — any body cell, not placenta; embryonic stem cells. Multipotent — one family; haematopoietic (blood and immune), mesenchymal (bone, cartilage, fat). iPSCs — adult cells reprogrammed to pluripotency; Shinya Yamanaka, Nobel 2012, shared with John Gurdon.
The proven use. Haematopoietic stem cell transplantation — bone marrow and cord blood — for leukaemias, lymphomas, aplastic anaemia, thalassaemia and certain immune deficiencies. Everything outside this core is investigational under the 2017 guidelines.
Why autism is hard. A neurodevelopmental condition with no single repairable lesion, and a natural course that includes genuine gains — so without a control arm, treatment effect cannot be separated from ordinary development.
Four instruments. National Guidelines for Stem Cell Research, 2017 — ICMR + DBT · Clinical Establishments Act, 2010, Sections 32 and 40 — cancellation of registration, penalty; acts on the institution · IMC Regulations, 2002, Regulation 7.22 — professional misconduct; acts on the practitioner · NMC, created by the NMC Act, 2019 replacing the MCI; directs State Medical Councils.
Article 252. Public health, hospitals and dispensaries = Entry 6, State List. The 2010 Act was enacted under Article 252 on resolutions by Arunachal Pradesh, Himachal Pradesh, Mizoram and Sikkim; applies to those four and the Union Territories from 1 March 2012; later adopted by Uttar Pradesh, Uttarakhand, Rajasthan, Bihar, Jharkhand and Assam. Amendable or repealable only by Parliament.
The related articles. Article 249 — Rajya Sabha resolution, two-thirds, national interest, one year. Article 250 — during a Proclamation of Emergency. Article 252 — voluntary, State-initiated.
What it is not. Not a ban on stem cell research in autism; not a finding that stem cell therapy is ineffective. A line between evidence and hope, with Para 151(xiii) attaching consequences.
🎯 Practice MCQs
Q1. The National Guidelines for Stem Cell Research, 2017 were issued jointly by: (a) CDSCO and NMC (b) ICMR and the Department of Biotechnology (c) DRDO and CSIR (d) NITI Aayog and the Ministry of Science and Technology
→ (b)
Q2. Cells that can differentiate into any cell type of the body but not extra-embryonic tissue such as the placenta are: (a) Totipotent (b) Pluripotent (c) Multipotent (d) Unipotent
→ (b) — totipotent cells can also form placental tissue.
Q3. The 2012 Nobel Prize in Physiology or Medicine, shared by Shinya Yamanaka, was awarded for work on: (a) Haematopoietic transplantation (b) Reprogramming mature cells to become pluripotent (c) Gene editing using CRISPR (d) Monoclonal antibodies
→ (b) — induced pluripotent stem cells; shared with John Gurdon.
Q4. The Clinical Establishments (Registration and Regulation) Act, 2010 was enacted by Parliament using: (a) Article 249 (b) Article 250 (c) Article 252 (d) Article 253
→ (c) — on resolutions passed by four State legislatures.
Q5. "Public health and sanitation, hospitals and dispensaries" appears in the: (a) Union List (b) State List (c) Concurrent List (d) Residuary powers
→ (b) — Entry 6, which is why Article 252 was needed.
Q6. The National Medical Commission replaced the Medical Council of India under an Act of: (a) 2016 (b) 2017 (c) 2019 (d) 2021
→ (c)
Q7. Which of the following is the long-established, evidence-backed clinical use of stem cells? (a) Stem cell infusion for autism spectrum disorder (b) Haematopoietic stem cell transplantation for leukaemia (c) Stem cell therapy for cerebral palsy (d) Stem cell injections for ageing
→ (b)
Q8. Under the Supreme Court's judgment, therapeutic use of stem cells in Autism Spectrum Disorder is: (a) Completely prohibited, including research (b) Permitted as standard care in registered hospitals (c) Restricted to duly approved clinical trials (d) Permitted with written parental consent
→ (c) — consent does not make an unapproved commercial intervention lawful.
Q9. A law made by Parliament under Article 252 can subsequently be amended or repealed by: (a) The legislature of any adopting State (b) Parliament only (c) The President by order (d) The Rajya Sabha alone
→ (b)
Q10. Consider the following statements: 1. Sections 32 and 40 of the Clinical Establishments Act, 2010 provide for cancellation of registration and penalty. 2. Regulation 7.22 of the IMC Regulations, 2002 is directed at the clinical establishment rather than the individual practitioner. Which is/are correct? (a) 1 only (b) 2 only (c) Both 1 and 2 (d) Neither 1 nor 2
→ (a) — the IMC Regulations govern the practitioner; the 2010 Act governs the establishment.
📋 How this gets asked (PYQ pattern)
Science-and-governance stories like this one are unusually productive for CDS and OTA, because a single event yields questions in three different sections of the paper.
As a science question, it becomes potency classification — totipotent, pluripotent, multipotent — or the Nobel attribution, or which condition has an established stem cell treatment. This is the most likely form, and it does not require knowing the judgment at all.
As a polity question, it becomes Article 252, or the State List entry on public health, or which body replaced the Medical Council of India. This is the higher-value form, because the Article 249/250/252 trio is a standing favourite and most candidates meet it only as abstract theory. A concrete statute they can attach to Article 252 is worth more than a memorised definition.
As a statement-pair question, it becomes the institution-versus-practitioner distinction, or the difference between prohibiting research and prohibiting commercial provision — the kind of fine line that statement pairs are built to test.
The efficient way to store this is a three-line note: the science (potency and the one proven use), the statute (Article 252 and the 2010 Act), and the regulator (ICMR-DBT guidelines, NMC, State Medical Councils). Those three lines answer every version of the question.
Preparing for CDS or OTA? Science stories carry their best marks in the polity section — the regulator, the statute and the constitutional route are what get asked. Build the base with our CDS/OTA general science notes, follow the daily CDS/OTA current affairs, and prepare with our faculty in the upcoming Cavalier courses in Delhi.
✍️ Written by The Cavalier — Science & current affairs desk at The Cavalier. Reviewed by the Cavalier Faculty Desk.